China's first indication! Roche VENTANA PD-L1 (SP263) test approved as an accompanying diagnosis for urinary disease

2020 Nian 5 15, the world leader in in vitro diagnostics, Roche Diagnostics announced VENTANAPD-L1 (SP263) detection formally approved the listing in ChinaThe detection of the tumor microenvironment by the tumor and immune cells were stained and scored to evaluate PD-L1 expression levels in patients, to provide information to guide treatment decisions for clinicians to improve the quality of life and survival of patients with urothelial carcinomaurothelial cancer is the major histological type of bladder cancer, accounting for about 90% of all bladder cancerAccording to the "2018 Global cancer statistics" shows that in 2018 the world's 549,393 new cases of bladder cancer cases, 199,922 cases of deathAmong them, our country expects new cases of bladder cancer, 82,270 cases, 38,208 cases of expected deathsas the current one of the most promising research in the field of cancer treatment, tumor immunotherapy by mobilization of body's immune system, enhancing antitumor immunity, thereby suppressing and killing tumor cellsClinical Advances in immunotherapy, programmed death factor 1 (programmeddeath1, PD-1) / factor ligand programmed death 1 (programmeddeathligand1, PD-L1) immunized checkpoint inhibitors recent breakthrough in cancer therapy, opened a new model for the field of cancer diagnosis and treatmentPD-L1 is an immunosuppressive protein, it can affect the body's ability to resist cancerStudies confirm, PD-L1 expression in patients more likely to benefit from immunotherapyTherefore, understanding the PD-L1 expression levels of great value for clinical diagnosis and treatmentas an adjunct diagnostic tool, VENTANAPD-L1 (SP263) for detecting a detection PD-L1 expression in urothelial carcinoma tumor cells and immune cells, to assess the patient's clinician PD- L1 stateIt is reported that the detection applicable to Roche Diagnostics BenchMarkULTRA automated immunohistochemical staining platformMrYao Guoliang, general manager of China Roche Diagnostics, said: "At present, urothelial cancer diagnosis and treatment, there are still areas of clinical need, doctors and patients are far from being satisfied an urgent need for a more effective treatment precise treatmentto detect in advancethe Roche VENTANAPD-L1 (SP263) to detect and Baiji China market and urothelial cancer immunotherapy products to achieve cooperation, reflects the Roche diagnostics China through innovative diagnostic solutions continued commitment to personalized medicine promisesurothelial carcinoma is VENTANAPD-L1 (SP263) detected in China's first listed indications in the future, we will continue to push for more indications in the detection of China approved to benefit more Chinese patients "< br /> on VENTANAPD-L1 (SP263) detecting VENTANAPD-L1 (SP263) detecting, for a growing number of cancer indications programmed death ligand (PD-L1) of qualitative testing The automatic detection suitable for immunohistochemical staining BenchMarkULTRA internet VENTANAPD-L1 (SP263) for evaluating PD-L1 expression in tumor or immune cell membrane of urothelial carcinoma, urothelial carcinoma help determine the possibility of an immune response an effective therapeutic tool About Roche Roche is a pioneer global pharmaceutical and diagnostics, committed to advancing science to improve people's lives The comprehensive advantages of pharmaceuticals and diagnostics Roche makes personalized medicine to become a leader Personalized healthcare strategy aims at providing each patient appropriate treatment in an optimal manner Roche is one of the leading biotechnology companies, providing truly differentiated tumor drugs, immunology, infectious diseases, ophthalmology and central nervous system diseases Is one of the world leader in in vitro diagnostics and tissue-based cancer diagnostics Roche, as well as a leader in the field of diabetes management founded in 1896, Roche continued to seek prevention, diagnosis and treatment of disease the best way, and make a sustained contribution to society Roche is also committed to working with all stakeholders, ways to improve patient access to innovative medical care Roche research and development of a variety of drugs are incorporated into 30 List of Essential Medicines World Health Organization, which include antibiotics, anti-malarial drugs and life-saving cancer drugs Roche has 11 consecutive years by the Dow Jones Sustainability Index as the most sustainable companies in the pharmaceutical industry Roche Headquartered in Basel, Switzerland, is active in more than 100 countries 2019, over 98,000 employees worldwide, has invested 11.7 billion Swiss francs in R & D, sales of 61.5 billion Swiss francs US-based Genentech Inc is a wholly owned subsidiary of the Roche Group Roche is also the majority owner of Chugai in Japan about Baiji Baiji Divine Divine is a global, commercial-stage biotechnology company focused on research, development, production, and commercialization of innovative drug that whole the world to improve the efficacy and patient access to medicines Baiji is currently in China mainland China, the United States, Australia and Europe with more than 3,500 employees, is to accelerate the diversification of the company's pipeline of new drugs for cancer therapy